Cellbox Solutions, a German warm-chain logistics technology company, announced on October 20, 2026, that it has completed the final closing of its Series A financing round. The round brought total proceeds to EUR 5 million. The company will use the capital to develop its business model and broaden its offering with integrated logistics solutions for sensitive biological materials, including cells, tissues, and organoids.
Financing Details and Investor Support
The Series A round followed an initial closing of approximately EUR 3.5 million in March 2026, which was led by Companisto. Since then, Cellbox Solutions has attracted additional investors including members of Baltic Business Angels Invest GmbH, a Canadian family office, and an undisclosed investor with deep experience in pharmaceutical logistics. Existing investors NRW.BANK and Fraunhofer Venture also participated in the final closing.
Closing this financing round marks the next phase in the company's commercial growth and will help leverage its technological, product-related, and regulatory advances. Cellbox Solutions has built strong capabilities in specialized transport that maintains controlled physiological conditions. The company now aims to connect that capability more closely with additional logistics and service offerings.
Technology Platform and Regulatory Foundation
Cellbox Go and Cellbox Shipper form the core of the company's technology platform. Both portable CO₂ incubators provide controlled temperature and CO₂ conditions during ground and air transport, and they are already used internationally in research and cell therapy applications. More than 400 Cellbox systems are currently on the market, supported by a regulatory foundation that includes Drug Master Files for the Cellbox product family.
This base positions the company to expand its commercial offering through rental and transport options as well as recurring services. Those services include monitoring, fleet management, and shipment coordination. The goal is to provide customers with greater flexibility and comprehensive support across their logistics processes, from initial shipment coordination to ongoing monitoring and fleet management.
Executive Commentary
Prof. Dr. Kathrin Adlkofer, Founder and CEO of Cellbox Solutions, said that the company has built a strong foundation for the controlled transport of living biological materials over the past years. She added that the successful Series A completion allows Cellbox Solutions to expand its established warm-chain technology platform into a broader physiological logistics offering. According to Adlkofer, this will help the company support customers more comprehensively and expand its presence in key international markets.
Dr. Bernd Muehlenweg, CBO and CFO of Cellbox Solutions, said the completion gives the company additional resources to scale the commercial model behind its technology. He noted that expanding rental and recurring service offerings, combined with transportation, monitoring, and complementary logistics services, can build longer-term customer relationships and a more scalable service model. Muehlenweg added that the focus is now on translating the strength of the Cellbox platform into sustainable commercial growth.
International Expansion and Market Focus
To support its commercial ambitions, Cellbox Solutions is expanding activities in Europe, Asia, and North America. The company is increasingly focusing on strategic partnerships with logistics providers. These efforts aim to broaden its customer base, strengthen its position in advanced therapy and life sciences supply chains, and support recurring service adoption in key international markets.
Company Background
Founded in 2017, Cellbox Solutions GmbH provides warm-chain logistics technology for the global healthcare and life sciences industries. Its portable CO₂ incubator platform, Cellbox, creates a regulated environment for transporting living cells, organoids, tissues, and other advanced biological materials that cannot be frozen. Temperature and CO₂ levels can be individually adjusted to ensure reproducible incubation conditions throughout shipment.
The completion of the Series A round strengthens Cellbox Solutions' ability to pursue integrated physiological logistics on a global scale. With new investors, a proven technology platform, and an expanding service model, the company is positioned for sustainable commercial growth. Its next phase will focus on deepening customer relationships and scaling its presence across key life sciences markets.